Haemonetics Stock Forecast, Price & News

Haemonetics (NYSE:HAE) Frequently Asked Questions

Is Haemonetics a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Haemonetics stock.
View analyst ratings for Haemonetics or view top-rated stocks.

How has Haemonetics' stock been impacted by COVID-19 (Coronavirus)?

Haemonetics' stock was trading at $103.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HAE stock has decreased by 51.3% and is now trading at $50.49.
View which stocks have been most impacted by COVID-19.

When is Haemonetics' next earnings date?

Haemonetics is scheduled to release its next quarterly earnings announcement on Tuesday, February 8th 2022.
View our earnings forecast for Haemonetics.

How can I listen to Haemonetics' earnings call?

Haemonetics will be holding an earnings conference call on Tuesday, February 8th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Haemonetics' earnings last quarter?

Haemonetics Co. (NYSE:HAE) posted its quarterly earnings results on Tuesday, November, 9th. The medical instruments supplier reported $0.60 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.61 by $0.01. The medical instruments supplier had revenue of $239.90 million for the quarter, compared to analysts' expectations of $240.85 million. Haemonetics had a trailing twelve-month return on equity of 17.19% and a net margin of 3.35%. The business's revenue was up 14.5% on a year-over-year basis. During the same quarter last year, the company earned $0.62 EPS.
View Haemonetics' earnings history.

What guidance has Haemonetics issued on next quarter's earnings?

Haemonetics updated its FY 2022 earnings guidance on Tuesday, December, 7th. The company provided EPS guidance of $2.400-$2.650 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.760. The company issued revenue guidance of $983.62 M-$1.02 billion, compared to the consensus revenue estimate of $1.01 billion.

What price target have analysts set for HAE?

8 equities research analysts have issued 1-year price objectives for Haemonetics' shares. Their forecasts range from $59.00 to $86.00. On average, they anticipate Haemonetics' stock price to reach $73.00 in the next year. This suggests a possible upside of 44.6% from the stock's current price.
View analysts' price targets for Haemonetics or view top-rated stocks among Wall Street analysts.

Who are Haemonetics' key executives?

Haemonetics' management team includes the following people:

• Christopher A. Simon, President, Chief Executive Officer & Director
• William Patrick Burke, Chief Financial Officer & Executive Vice President
• Anila Lingamneni, Chief Technology Officer & Executive VP
• Michelle L. Basil, Secretary, Executive VP & General Counsel (LinkedIn Profile)
• Dan Goldstein, Vice President & Controller

What is Christopher Simon's approval rating as Haemonetics' CEO?

48 employees have rated Haemonetics CEO Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among Haemonetics' employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Haemonetics' key competitors?

Some companies that are related to Haemonetics include Align Technology (ALGN), West Pharmaceutical Services (WST), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Quidel (QDEL), ICU Medical (ICUI), Neogen (NEOG), STAAR Surgical (STAA), Merit Medical Systems (MMSI), Atrion (ATRI), Cerus (CERS), Meridian Bioscience (VIVO), OraSure Technologies (OSUR), Antares Pharma (ATRS) and Anika Therapeutics (ANIK).
View all of HAE's competitors.

What other stocks do shareholders of Haemonetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), (APA), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

What is Haemonetics' stock symbol?

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Who are Haemonetics' major shareholders?

Haemonetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include LGT Capital Partners LTD. (2.38%), Diversified Trust Co (0.02%), Cardinal Capital Management (0.02%), State of Alaska Department of Revenue (0.01%), Crossmark Global Holdings Inc. (0.01%) and Spire Wealth Management (0.00%). Company insiders that own Haemonetics stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Mark W Kroll, Michelle L Basil, Michelle L Basil, Richard J Meelia, Stewart W Strong and William P Mr Burke.
View institutional ownership trends for Haemonetics.

Which institutional investors are selling Haemonetics stock?

HAE stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Haemonetics company stock in the last year include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Mark W Kroll, Michelle L Basil, Richard J Meelia, Stewart W Strong, and William P Mr Burke.
View insider buying and selling activity for Haemonetics or view top insider-selling stocks.

Which institutional investors are buying Haemonetics stock?

HAE stock was purchased by a variety of institutional investors in the last quarter, including LGT Capital Partners LTD., Diversified Trust Co, Spire Wealth Management, Crossmark Global Holdings Inc., and Cardinal Capital Management.
View insider buying and selling activity for Haemonetics or or view top insider-buying stocks.

How do I buy shares of Haemonetics?

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Haemonetics' stock price today?

One share of HAE stock can currently be purchased for approximately $50.49.

How much money does Haemonetics make?

Haemonetics has a market capitalization of $2.58 billion and generates $870.46 million in revenue each year. The medical instruments supplier earns $79.47 million in net income (profit) each year or $0.60 on an earnings per share basis.

How many employees does Haemonetics have?

Haemonetics employs 2,708 workers across the globe.

When was Haemonetics founded?

Haemonetics was founded in 1971.

What is Haemonetics' official website?

The official website for Haemonetics is www.haemonetics.com.

Where are Haemonetics' headquarters?

Haemonetics is headquartered at 125 Summer Street, Boston MA, 02110.

How can I contact Haemonetics?

Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The medical instruments supplier can be reached via phone at (781) 848-7100, via email at [email protected], or via fax at 781-848-5106.